Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-01-06
|
Oncoprex™ and erlotinib |
late non-small cell lung cancer (NSCLC) |
2 |
Genprex (USA - TX |
Cancer - Oncology |
2017-01-05
|
BioChaperone Lispro® (insuline lispro) and Symlin® (pramlintide), BioChaperone Lispro® (insuline lispro) and Byetta®(exenatide) |
type 1 diabetes |
1 |
Adocia (France) |
Metabolic diseases |
2017-01-05
|
SGN-CD352A |
multiple myeloma |
1 |
Seattle Genetics (USA - WA) |
Cancer - Oncology |
2017-01-05
|
sulopenem |
multi-drug resistant infections |
3 |
Iterum Therapeutics (Ireland) |
Infectious diseases |
2017-01-05
|
microbiome computational platform |
|
|
RondinX (Israel) |
Inflammatory diseases - Gastrointestinal diseases - Metabolic diseases |
2017-01-05
|
sitravatinib (MGCD516) |
advanced solid tumors |
1b |
Mirati Therapeutics (USA - CA) |
Cancer - Oncology |
2017-01-05
|
glesatinib (MGCD265) |
non-small cell lung cancer (NSCLC) |
2 |
Mirati Therapeutics (USA - CA) |
Cancer - Oncology |
2017-01-05
|
arhalofenate |
gout |
3 |
Cymabay Therapeutics (USA - CA) |
Inflammatory diseases |
2017-01-05
|
ceramide nanoliposome |
solid tumors |
1-2 |
Keystone Nano (USA - PA) |
Cancer - Oncology |
2017-01-05
|
SL-401 - recombinant human interleukin-3 truncated diphtheria toxin fusion protein |
blastic plasmacytoid dendritic cell neoplasm |
1-2 |
Stemline Therapeutics (USA - NY) |
Cancer - Oncology |
2017-01-05
|
pacritinib |
myelofibrosis |
3 |
CTI BioPharma - previously known as Cell Therapeutics (USA - WA) - Baxalta (USA - IL) |
Cancer - Oncology |
2017-01-04
|
navicixizumab - anti-DLL4/VEGF bispecific antibody (OMP-305B83) |
metastatic colorectal cancer |
1 |
OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2017-01-04
|
ISIS-GCGR Rx |
type 2 diabetes |
2 |
Isis Pharmaceuticals (USA) |
Metabolic diseases |
2017-01-04
|
TGR-1202 plus ibrutinib |
diffuse large B-cell lymphoma (DLBCL) |
2 |
TG Therapeutics (USA - NY) National Cancer Institute (NCI) (USA) |
Cancer - Oncology |
2017-01-04
|
Prostvac® (rilimogene) |
asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) |
3 |
Bavarian Nordic (Denmark) |
Cancer - Oncology |
2017-01-03
|
IVA337 - lanifibranor - 1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid |
NASH (non-alcoholic steatohepatitis) |
2 |
Inventiva Pharma (France) |
Hepatic diseases - Liver diseases |
2017-01-03
|
IMP761 |
|
|
Prima Biomed (Australia) |
Autoimmune diseases |
2017-01-03
|
coversin (recombinant protein derived from the saliva of the Ornithodoros moubata tick) |
paroxysmal nocturnal hemoglobinuria (PNH) |
2 |
Akari Therapeutics (USA - NY - UK) |
Rare diseases - Immunological diseases |
2017-01-03
|
ibalizumab |
HIV-1 infection |
3 |
TaiMed Biologics (Taiwan) Theratechnologies (Canada) |
Infectious diseases |
2017-01-02
|
MM-302 |
breast cancer |
2-3 |
Merrimack Pharmaceuticals (USA - MA) |
Cancer - Oncology |